BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36067510)

  • 1. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
    Lu Y; Sun RJ; Zhang JP; Xu F; Du ZC; Tong GL; Wang Y; Lu DP
    Leuk Lymphoma; 2022 Dec; 63(13):3092-3099. PubMed ID: 36067510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].
    Cheng P; Wang LL; Wang QX; Guan J; Zhou Y; Hu B; Feng Y; Zou L; Cheng H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1531-1536. PubMed ID: 37846712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
    Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
    Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
    Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
    Murthy HS; Zhang MJ; Chen K; Ahmed S; Deotare U; Ganguly S; Kansagra A; Michelis FV; Nishihori T; Patnaik M; Abid MB; Aljurf M; Arai Y; Bacher U; Badar T; Badawy SM; Ballen K; Battiwalla M; Beitinjaneh A; Bejanyan N; Bhatt VR; Brown VI; Martino R; Cahn JY; Castillo P; Cerny J; Chhabra S; Copelan E; Daly A; Dholaria B; Diaz Perez MA; Freytes CO; Grunwald MR; Hashmi S; Hildebrandt GC; Jamy O; Joseph J; Kanakry CG; Khera N; Krem MM; Kuwatsuka Y; Lazarus HM; Lekakis LJ; Liu H; Modi D; Munshi PN; Mussetti A; Palmisiano N; Patel SS; Rizzieri DA; Seo S; Shah MV; Sharma A; Sohl M; Solomon SR; Ulrickson M; Ustun C; van der Poel M; Verdonck LF; Wagner JL; Wang T; Wirk B; Zeidan A; Litzow M; Kebriaei P; Hourigan CS; Weisdorf DJ; Saber W; Kharfan-Dabaja MA
    Blood Adv; 2023 Nov; 7(22):7007-7016. PubMed ID: 37792849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters.
    Bruch PM; Dietrich S; Finel H; Boumendil A; Greinix H; Heinicke T; Bethge W; Beelen D; Schmid C; Martin H; Castagna L; Scheid C; Schäfer-Eckart K; Bittenbring J; Finke J; Sengeloev H; Heiblig M; Cornelissen J; Chevallier P; Mohty M; Robinson S; Montoto S; Dreger P
    Leukemia; 2023 Feb; 37(2):465-472. PubMed ID: 36550212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm.
    Huang X; Wang S; Xu Y; Mei C; Han Q; Wu X; Du F; Ren Y; Jin J; Tong H; Qian J
    Ann Hematol; 2024 Jun; 103(6):2165-2168. PubMed ID: 38584216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Bashir Q; Milton DR; Popat UR; Kebriaei P; Hosing C; Khouri IF; Rezvani K; Nieto Y; Oran B; Srour SA; Saini NY; Olson AL; Ahmed S; Al-Atrash G; Rondon G; Konopleva MY; Champlin RE; Shpall EJ; Qazilbash MH; Pemmaraju N
    Bone Marrow Transplant; 2022 Jan; 57(1):51-56. PubMed ID: 34629467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
    Roos-Weil D; Dietrich S; Boumendil A; Polge E; Bron D; Carreras E; Iriondo Atienza A; Arcese W; Beelen DW; Cornelissen JJ; Kröger N; Milone G; Rossi G; Jardin F; Peters C; Rocha V; Sureda A; Mohty M; Dreger P;
    Blood; 2013 Jan; 121(3):440-6. PubMed ID: 23203822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 13. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
    Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
    Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
    Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
    Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
    J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
    Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
    Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm.
    Aoki T; Suzuki R; Kuwatsuka Y; Kako S; Fujimoto K; Taguchi J; Kondo T; Ohata K; Ito T; Kamoda Y; Fukuda T; Ichinohe T; Takeuchi K; Izutsu K; Suzumiya J
    Blood; 2015 Jun; 125(23):3559-62. PubMed ID: 25918345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.